Table III.
Statistical analysis of risk factors for progression-free survival time of patients with colorectal cancer.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Characteristic | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age, years (<65 vs. ≥65) | 0.788 | 0.524–1.187 | 0.255 | |||
| Sex (male vs. female) | 1.011 | 0.671–1.522 | 0.959 | |||
| CEA level, µg/ml (<4.5 vs. ≥4.5) | 1.012 | 0.667–1.535 | 0.957 | |||
| CA19-9, U/ml (<50 vs. ≥50) | 1.104 | 0.733–1.663 | 0.635 | |||
| Tumor location (colon vs. rectum) | 1.032 | 0.677–1.572 | 0.884 | |||
| Differentiation (poor vs. well+moderate) | 1.566 | 1.038–2.363 | 0.033 | 1.483 | 0.975–2.254 | 0.065 |
| Tumor size, cm (≥5 vs. <5) | 1.059 | 0.699–1.604 | 0.786 | |||
| T stage (T1+T2 vs. T3+T4) | 1.908 | 1.228–2.965 | 0.004 | 1.310 | 0.812–2.114 | 0.269 |
| N stage (N1+N2 vs. N0) | 3.162 | 2.055–4.868 | <0.001 | 1.566 | 0.196–12.523 | 0.673 |
| M stage (M1 vs. M0) | 4.793 | 2.843–8.081 | <0.001 | 4.263 | 2.382–7.630 | <0.001 |
| TNM stage (III+IV vs. I+II) | 3.264 | 2.114–5.040 | <0.001 | 1.445 | 0.178–11.693 | 0.730 |
| NKILA expression (high vs. low) | 0.889 | 0.820–0.964 | 0.005 | 0.910 | 0.833–0.994 | 0.036 |
NKILA, nuclear factor-κB interacting long non-coding RNA; CEA, carcinoembryonic antigen; CA19-9, cancer antigen 19-9; TNM, Tumor-Node-Metastasis; CI, confidence interval; HR, hazard ratio.